HomeArcus Biosciences, Inc.

Trade Arcus Biosciences, Inc. - RCUS CFD

Market is not available at the momentMarket information is presented
as of 2026-11-19T20:48:49+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.09
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02226 %
(-$2.23)

Trade size with leverage ~ $10,000.00

Money from leverage ~ $$9,000.00


-0.02226%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00004 %
($0.00)

Trade size with leverage ~ $10,000.00

Money from leverage ~ $$9,000.00


0.00004%
Overnight funding adjustment time22:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin10.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close15.73
Open15.84
1-Year Change-21.51%
Day's Range15.6 - 16.14

Trade Arcus Biosciences, Inc. - RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company''s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.; and co-development and co-commercialization partnership with Gilead Sciences, Inc. for the development of cancer immunotherapies. The company was founded in 2015 and is based in Hayward, California.

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready